Building a Pipeline
of Immunotherapies

Gritstone is building a pipeline of immunotherapy product candidates for patients with solid tumors. Our first product candidate, GRANITE-001, is a personalized neoantigen-based immunotherapy. It is being evaluated in a Phase 1/2 clinical study in combination with checkpoint inhibitors for patients with common solid tumors, including metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, gastroesophageal cancer, and bladder cancer. GRANITE-001 has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of colorectal cancer.

Our second product candidate, SLATE-001, will utilize the same antigen delivery system as GRANITE-001 but contains a fixed set of neoantigens that are shared across a subset of cancer patients rather than neoantigens unique to an individual patient, providing us with an off-the-shelf alternative to GRANITE-001. We expect to enter human clinical trials for SLATE-001 in the second half of 2019.

Additionally, we have a program focused on the development of bispecific antibody (BiSAb) therapeutics using highly tumor-specific antigens, including neoantigens, shared between patients with various solid tumors. Our BiSAb program is currently in lead optimization.

Gritstone is also leveraging EDGE™ as a unique antigen discovery platform to define targets for other immunotherapies such as T-cell receptor (TCR) directed cell therapies and bispecific antibody therapies. These additional targets that were identified and validated by EDGE™ enable us to partner with others or develop additional therapeutic approaches to redirect T cells onto tumors using these highly specific targets.

For a description of our ongoing clinical studies, please visit clinicaltrials.gov. An overview of our compassionate use policy can be found here.

Making
an Impact

We are committed to progressing the field of immunotherapy, with a goal to eradicate cancer by initially developing personalized immunotherapies that focus on the unique and individual nature of a patient’s tumor. Our dynamic team combines novel science with focus on team work, and we are looking for passionate, innovative people to join us.

Top